PMID- 33549065
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Feb 6
TI  - Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in 
      postmenopausal women with previously untreated advanced cervical cancer: a 
      retrospective study.
PG  - 133
LID - 10.1186/s12885-021-07869-7 [doi]
LID - 133
AB  - BACKGROUND: The aim of this study was to assess the survival outcomes of 
      cisplatin-paclitaxel chemotherapy plus bevacizumab (CPB) versus 
      cisplatin-paclitaxel chemotherapy alone (CPA) in postmenopausal women with 
      previously untreated advanced cervical cancer (CC). METHODS: Consecutive 
      postmenopausal women who experienced CPB or CPA were identified retrospectively 
      from our medical centre during 2015-2019. Follow-up visits occurred 1 and 
      3 months after starting CPB or CPA. Afterwards, this assessment was conducted 
      every 3 months for 1 year and then yearly thereafter. The primary endpoints were 
      overall survival (OS) and progression-free survival (PFS); secondary endpoints 
      were the frequency and severity of adverse events (AEs). RESULTS: Two hundred 
      forty-six postmenopausal women were included (CPB, n = 124; CPA, n = 122). The 
      median follow-up for the entire cohort was 24 months (range, 2-32). At the final 
      follow-up, a significant difference was detected in terms of median OS 
      (16.4 months [95% CI, 15.3-17.1] for CPB vs. 12.3 months [95% CI, 10.2-13.5] for 
      CPA; hazard ratio (HR) 0.69, 95% CI, 0.49-0.99; p = 0.001), and the median PFS 
      was longer in the CPB group than in the CPA group (9.2 months [95% CI, 8.3-10.7] 
      vs. 7.9 months (95% CI, 6.1-8.6) (HR 0.62, 95% CI, 0.47-0.82; p < 0.001). There 
      were significant differences in the number of AEs between the groups 
      (hypertension grade >/= 2 [p < 0.001], neutropenia grade >/= 4 [p < 0.001], and 
      thrombosis/embolism grade >/= 3 [p = 0.030]). CONCLUSIONS: Among postmenopausal 
      women with previously untreated advanced CC, those who received CPB experienced 
      superior survival benefits compared to those who received CPA. The safety profile 
      for CPB was controllable despite the long duration of CPB use.
FAU - Chu, Guanghua
AU  - Chu G
AD  - Department of Gynecology, Northwest Women's and Children's Hospital, No. 1616, 
      Yanxiang Road, Qujiang New District, Xi'an, 710061, Shaanxi, China.
FAU - Liu, Xiangzhen
AU  - Liu X
AD  - Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Sun 
      Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 
      510080, China.
FAU - Yu, Weiguang
AU  - Yu W
AD  - Department of Orthopedics, The First Affiliated Hospital, Sun Yat-sen University, 
      No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
FAU - Chen, Meiji
AU  - Chen M
AD  - Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, 
      No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
FAU - Dong, Lingyun
AU  - Dong L
AD  - Department of Gynecology and obstetrics, Shanghai Public Health Clinical Center, 
      No. 2901 Caolang Road, Jinshan District, Shanghai, 201508, China. 
      donglingyun@aliyun.com.
LA  - eng
PT  - Journal Article
DEP - 20210206
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - TP protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bevacizumab/adverse effects/*therapeutic use
MH  - Cisplatin/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Paclitaxel/adverse effects/therapeutic use
MH  - *Postmenopause
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Uterine Cervical Neoplasms/*drug therapy/mortality/pathology
PMC - PMC7866467
OTO - NOTNLM
OT  - Advanced
OT  - Bevacizumab
OT  - Cervical cancer
OT  - Chemotherapy
OT  - Survival
COIS- The authors declare that they have no competing interests.
EDAT- 2021/02/08 06:00
MHDA- 2021/09/03 06:00
PMCR- 2021/02/06
CRDT- 2021/02/07 20:26
PHST- 2020/10/08 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/07 20:26 [entrez]
PHST- 2021/02/08 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2021/02/06 00:00 [pmc-release]
AID - 10.1186/s12885-021-07869-7 [pii]
AID - 7869 [pii]
AID - 10.1186/s12885-021-07869-7 [doi]
PST - epublish
SO  - BMC Cancer. 2021 Feb 6;21(1):133. doi: 10.1186/s12885-021-07869-7.